Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

David M. Jackman, Beow Y. Yeap, Lecia V. Sequist, Neal Lindeman, Alison J. Holmes, Victoria A. Joshi, Daphne W. Bell, Mark S. Huberman, Balazs Halmos, Michael S. Rabin, Daniel A. Haber, Thomas J. Lynch, Matthew Meyerson, Bruce E. Johnson, Pasi A. Jänne

Research output: Contribution to journalArticle

437 Citations (Scopus)

Abstract

Purpose: Somatic mutations in the epidermal growth factor receptor (EGFR) have been detected in patients with non - small cell lung cancer (NSCLC) and are associated with sensitivity to treatment with gefitinib or erlotinib, Our study explored the relationship between the two most common types of somatic EGFR mutations, exon 19 deletions and the L858R point mutation, and outcomes of patients following treatment with gefitinib or erlotinib. Experimental Design: Tumor specimens obtained before treatment with gefitinib or erlotinib were analyzed for EGFR mutations. Patients with exon 19 deletion or L858R mutations were identified. The response rate, time to progression, and overall survival were determined for the two groups. Results: We identified 36 patients with NSCLC and an EGFR mutation who were treated with gefitinib or erlotinib. Patients with an exon 19 deletion had a significantly longer overall survival compared with patients with an L858R mutation (38 versus 17 months; P = 0.04). There were also trends toward higher response rate (73% versus 50%) and improved time to progression (24 versus 10 months) for the patients with an exon 19 deletion, although these were not independently significant in a multivariate analysis. A difference in response rate for patients treated with gefitinib compared with erlotinib was also noted [18 of 23 (78%) versus 3 of 9 (33%); P = 0.04]. No obvious difference in time to progression or overall survival was noted between gefitinib- and erlotinib-treated patients. Conclusions: Patients with NSCLC and EGFR exon 19 deletions have a longer survival following treatment with gefitinib or erlotinib compared with those with the L858R mutation. Pooling of greater numbers of patients and completion of prospective trials are needed to further define the predictive and prognostic roles of different EGFR mutations with respect to treatment with gefitinib, erlotinib, and other EGFR inhibitors.

Original languageEnglish (US)
Pages (from-to)3908-3914
Number of pages7
JournalClinical Cancer Research
Volume12
Issue number13
DOIs
StatePublished - Jul 1 2006
Externally publishedYes

Fingerprint

Sequence Deletion
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Exons
Survival
Mutation
gefitinib
Erlotinib Hydrochloride
Therapeutics
Point Mutation
Research Design
Multivariate Analysis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. / Jackman, David M.; Yeap, Beow Y.; Sequist, Lecia V.; Lindeman, Neal; Holmes, Alison J.; Joshi, Victoria A.; Bell, Daphne W.; Huberman, Mark S.; Halmos, Balazs; Rabin, Michael S.; Haber, Daniel A.; Lynch, Thomas J.; Meyerson, Matthew; Johnson, Bruce E.; Jänne, Pasi A.

In: Clinical Cancer Research, Vol. 12, No. 13, 01.07.2006, p. 3908-3914.

Research output: Contribution to journalArticle

Jackman, DM, Yeap, BY, Sequist, LV, Lindeman, N, Holmes, AJ, Joshi, VA, Bell, DW, Huberman, MS, Halmos, B, Rabin, MS, Haber, DA, Lynch, TJ, Meyerson, M, Johnson, BE & Jänne, PA 2006, 'Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib', Clinical Cancer Research, vol. 12, no. 13, pp. 3908-3914. https://doi.org/10.1158/1078-0432.CCR-06-0462
Jackman, David M. ; Yeap, Beow Y. ; Sequist, Lecia V. ; Lindeman, Neal ; Holmes, Alison J. ; Joshi, Victoria A. ; Bell, Daphne W. ; Huberman, Mark S. ; Halmos, Balazs ; Rabin, Michael S. ; Haber, Daniel A. ; Lynch, Thomas J. ; Meyerson, Matthew ; Johnson, Bruce E. ; Jänne, Pasi A. / Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. In: Clinical Cancer Research. 2006 ; Vol. 12, No. 13. pp. 3908-3914.
@article{b94a065fad5046a8b4a3ce3f2f5a9611,
title = "Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib",
abstract = "Purpose: Somatic mutations in the epidermal growth factor receptor (EGFR) have been detected in patients with non - small cell lung cancer (NSCLC) and are associated with sensitivity to treatment with gefitinib or erlotinib, Our study explored the relationship between the two most common types of somatic EGFR mutations, exon 19 deletions and the L858R point mutation, and outcomes of patients following treatment with gefitinib or erlotinib. Experimental Design: Tumor specimens obtained before treatment with gefitinib or erlotinib were analyzed for EGFR mutations. Patients with exon 19 deletion or L858R mutations were identified. The response rate, time to progression, and overall survival were determined for the two groups. Results: We identified 36 patients with NSCLC and an EGFR mutation who were treated with gefitinib or erlotinib. Patients with an exon 19 deletion had a significantly longer overall survival compared with patients with an L858R mutation (38 versus 17 months; P = 0.04). There were also trends toward higher response rate (73{\%} versus 50{\%}) and improved time to progression (24 versus 10 months) for the patients with an exon 19 deletion, although these were not independently significant in a multivariate analysis. A difference in response rate for patients treated with gefitinib compared with erlotinib was also noted [18 of 23 (78{\%}) versus 3 of 9 (33{\%}); P = 0.04]. No obvious difference in time to progression or overall survival was noted between gefitinib- and erlotinib-treated patients. Conclusions: Patients with NSCLC and EGFR exon 19 deletions have a longer survival following treatment with gefitinib or erlotinib compared with those with the L858R mutation. Pooling of greater numbers of patients and completion of prospective trials are needed to further define the predictive and prognostic roles of different EGFR mutations with respect to treatment with gefitinib, erlotinib, and other EGFR inhibitors.",
author = "Jackman, {David M.} and Yeap, {Beow Y.} and Sequist, {Lecia V.} and Neal Lindeman and Holmes, {Alison J.} and Joshi, {Victoria A.} and Bell, {Daphne W.} and Huberman, {Mark S.} and Balazs Halmos and Rabin, {Michael S.} and Haber, {Daniel A.} and Lynch, {Thomas J.} and Matthew Meyerson and Johnson, {Bruce E.} and J{\"a}nne, {Pasi A.}",
year = "2006",
month = "7",
day = "1",
doi = "10.1158/1078-0432.CCR-06-0462",
language = "English (US)",
volume = "12",
pages = "3908--3914",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

AU - Jackman, David M.

AU - Yeap, Beow Y.

AU - Sequist, Lecia V.

AU - Lindeman, Neal

AU - Holmes, Alison J.

AU - Joshi, Victoria A.

AU - Bell, Daphne W.

AU - Huberman, Mark S.

AU - Halmos, Balazs

AU - Rabin, Michael S.

AU - Haber, Daniel A.

AU - Lynch, Thomas J.

AU - Meyerson, Matthew

AU - Johnson, Bruce E.

AU - Jänne, Pasi A.

PY - 2006/7/1

Y1 - 2006/7/1

N2 - Purpose: Somatic mutations in the epidermal growth factor receptor (EGFR) have been detected in patients with non - small cell lung cancer (NSCLC) and are associated with sensitivity to treatment with gefitinib or erlotinib, Our study explored the relationship between the two most common types of somatic EGFR mutations, exon 19 deletions and the L858R point mutation, and outcomes of patients following treatment with gefitinib or erlotinib. Experimental Design: Tumor specimens obtained before treatment with gefitinib or erlotinib were analyzed for EGFR mutations. Patients with exon 19 deletion or L858R mutations were identified. The response rate, time to progression, and overall survival were determined for the two groups. Results: We identified 36 patients with NSCLC and an EGFR mutation who were treated with gefitinib or erlotinib. Patients with an exon 19 deletion had a significantly longer overall survival compared with patients with an L858R mutation (38 versus 17 months; P = 0.04). There were also trends toward higher response rate (73% versus 50%) and improved time to progression (24 versus 10 months) for the patients with an exon 19 deletion, although these were not independently significant in a multivariate analysis. A difference in response rate for patients treated with gefitinib compared with erlotinib was also noted [18 of 23 (78%) versus 3 of 9 (33%); P = 0.04]. No obvious difference in time to progression or overall survival was noted between gefitinib- and erlotinib-treated patients. Conclusions: Patients with NSCLC and EGFR exon 19 deletions have a longer survival following treatment with gefitinib or erlotinib compared with those with the L858R mutation. Pooling of greater numbers of patients and completion of prospective trials are needed to further define the predictive and prognostic roles of different EGFR mutations with respect to treatment with gefitinib, erlotinib, and other EGFR inhibitors.

AB - Purpose: Somatic mutations in the epidermal growth factor receptor (EGFR) have been detected in patients with non - small cell lung cancer (NSCLC) and are associated with sensitivity to treatment with gefitinib or erlotinib, Our study explored the relationship between the two most common types of somatic EGFR mutations, exon 19 deletions and the L858R point mutation, and outcomes of patients following treatment with gefitinib or erlotinib. Experimental Design: Tumor specimens obtained before treatment with gefitinib or erlotinib were analyzed for EGFR mutations. Patients with exon 19 deletion or L858R mutations were identified. The response rate, time to progression, and overall survival were determined for the two groups. Results: We identified 36 patients with NSCLC and an EGFR mutation who were treated with gefitinib or erlotinib. Patients with an exon 19 deletion had a significantly longer overall survival compared with patients with an L858R mutation (38 versus 17 months; P = 0.04). There were also trends toward higher response rate (73% versus 50%) and improved time to progression (24 versus 10 months) for the patients with an exon 19 deletion, although these were not independently significant in a multivariate analysis. A difference in response rate for patients treated with gefitinib compared with erlotinib was also noted [18 of 23 (78%) versus 3 of 9 (33%); P = 0.04]. No obvious difference in time to progression or overall survival was noted between gefitinib- and erlotinib-treated patients. Conclusions: Patients with NSCLC and EGFR exon 19 deletions have a longer survival following treatment with gefitinib or erlotinib compared with those with the L858R mutation. Pooling of greater numbers of patients and completion of prospective trials are needed to further define the predictive and prognostic roles of different EGFR mutations with respect to treatment with gefitinib, erlotinib, and other EGFR inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=33746034167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746034167&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-06-0462

DO - 10.1158/1078-0432.CCR-06-0462

M3 - Article

VL - 12

SP - 3908

EP - 3914

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 13

ER -